

## Diaverum launches [kidney.com](https://kidney.com) in Portugal, advancing AI-powered education to support the global fight against Chronic Kidney Disease

- Developed in collaboration with M42 – a global health leader powered by artificial intelligence (AI), technology and genomics – [kidney.com](https://kidney.com) combines Diaverum’s three decades of clinical expertise with M42’s advanced AI capabilities to help patients, caregivers and healthcare professionals better understand both chronic and acute kidney diseases.
- [kidney.com](https://kidney.com) signals a broader shift in the use of generative AI with natural language in healthcare, moving from general-purpose models to specialised, condition-focused systems capable of understanding medical nuances, strengthening patient engagement and promoting health literacy.
- In Portugal, the 2024 national registry shows that among patients receiving haemodialysis, 27.7% have diabetes and 12.1% have hypertension as the primary kidney disease.

**Portugal, 13 May 2026** – As chronic kidney disease (CKD) becomes one of the fastest-growing global health challenges, placing increasing pressure on patients, communities and healthcare systems, **Diaverum**, a Swedish-born global renal care provider and part of M42, today announced the launch of [kidney.com](https://kidney.com), a new AI-powered health assistant. Designed to make kidney health education more accessible, personalised and grounded in trusted sources, the platform is available from today in Portugal, the United Arab Emirates, France, the United Kingdom and Germany, with additional markets to follow.

With up to 90% of people unaware they have chronic kidney disease until advanced stages, and many lacking the knowledge or resources needed to slow its progression, [kidney.com](https://kidney.com) provides free, accessible, interactive and personalised education.

Through a conversational AI interface trained on credible clinical sources, evidence-based content on chronic and acute kidney diseases, and learning experiences tailored to each user’s needs, [kidney.com](https://kidney.com) aims to increase awareness and help address this growing condition.

Studies show that patients with low health literacy are more likely to be hospitalised, highlighting how education improves health outcomes, reduces healthcare system costs and helps tackle inequalities. Additional features include voice control, product label interpretation through file uploads and multilingual support, with interfaces already available in English, Arabic, French, German and Portuguese, and more languages to be introduced soon.

**Dimitris Moulavasilis, Group CEO of M42**, said: *“At M42, we are reinventing how technology can enable healthier lives. [kidney.com](https://kidney.com) harnesses the power of advanced natural language AI to address one of the world’s fastest-growing lifestyle-related conditions. By combining trusted clinical expertise*

*with intelligent technology, kidney.com helps patients, caregivers and communities make informed decisions about their health. This is a clear example of how responsible AI can make care smarter, empowering people to manage and ultimately change the trajectory of chronic kidney disease.”*

CKD is also one of the most costly chronic diseases for healthcare systems: in Europe alone, annual costs are estimated at €140 billion.

In Portugal, the 2024 national registry shows that among patients receiving haemodialysis, 27.7% have diabetes and 12.1% have hypertension as the primary kidney disease. These figures highlight the significant impact of chronic conditions such as diabetes and hypertension on renal care. With more than 21,000 patients undergoing renal replacement therapy, the scale of the challenge is evident. Early education, prevention and self-management are critical — and these are precisely the areas where kidney.com aims to make a tangible difference.

**Rafael Romanini, CEO of Diaverum, commented:** *“At Diaverum, combining science with compassion to drive meaningful progress in renal care is at the heart of our DNA. With kidney.com, we are bringing this philosophy into the digital world, using AI-powered education to make kidney health knowledge accessible, relevant and actionable for everyone, everywhere, 24 hours a day. This initiative reflects our broader commitment to helping people live fulfilling lives while also supporting the sustainability of healthcare systems through education, prevention and innovation.”*

As healthcare evolves beyond general-purpose AI, kidney.com reflects a shift towards specialised, condition-focused systems designed to support real-world care. To ensure quality and relevance of information, kidney.com was developed in collaboration with more than 30 nephrologists, physicians and nurses from 13 countries, and underwent more than 14,000 interactions during testing before launch.

Although it is not a medical device and is not intended to diagnose or recommend treatments, kidney.com complements professional medical guidance, supports proactive self-management and has been developed in compliance with applicable privacy and data protection regulations.

**Dr. Carlos Lucas, VP at Diaverum** believes that: *“Clear, reliable and accessible information is essential for achieving better patient clinical outcomes. When patients understand their condition and treatment, they are more likely to actively engage in their care, follow medical recommendations and make informed decisions that contribute to better health. kidney.com translates complex, evidence-based kidney care knowledge, built on Diaverum’s 35 years of experience and expertise into personalised guidance, complementing rather than replacing the vital role played by healthcare professionals.”*

kidney.com translates complex kidney care knowledge into simple, evidence-based guidance that reinforces rather than replaces the vital role of physicians. It supports healthcare teams by encouraging informed conversations and shared decision-making, helping clinicians deliver more personalised, preventive and effective care.

The launch of kidney.com reinforces the joint commitment of Diaverum and M42 to building next-generation healthcare systems powered by AI, data and intelligence. It sets a new benchmark beyond general-purpose AI, with specialised, human-centred systems that transform knowledge into practical understanding to empower individuals and promote smarter, data-driven care.

## Notes to editors

What [kidney.com](https://www.kidney.com) offers

- [AI-powered large language model with a conversational chatbot interface](#)
- Evidence-based content on kidney health and the treatment of chronic and acute kidney diseases
- AI-driven personalisation, providing tailored educational materials
- Simple and accessible explanations to help people understand complex medical topics
- Free access, currently available online in Portugal, the United Arab Emirates, France, the United Kingdom and Germany, with plans to expand into additional markets by the end of the year. Beta versions are already available for testing in other European and Latin American countries where the company operates
- Additional interactive features for registered users — including voice control and the ability to upload files (e.g. photos of product labels) to receive educational insights
- Multilingual functionality: AI responses and chatbot interface available in Portuguese, Arabic, English, French and German, with more languages to be launched by the end of the year
- A tutorial video is available [here](#)

### About [Diaverum](#)

Diaverum is a Swedish-born multinational healthcare organisation providing renal care that improves the quality of life of patients living with chronic kidney disease, empowering them to live fulfilling lives. Our vision is to transform renal care by delivering and expanding access to the highest quality kidney care for patients around the world. At the core of our operations is a standardised care delivery model, an evolving digital and AI infrastructure, and people who care for patients with competence, passion and inspiration.

As a global leader and the largest independent renal care provider in Europe, we have 14,200 healthcare professionals caring for approximately 45,000 patients across more than 460 clinics in 25 countries worldwide. We provide personalised renal care aligned with patients' needs and choices, offering treatments ranging from preventive care, haemodialysis, peritoneal dialysis and home care, to the coordination of patient comorbidities and holiday dialysis.

Founded in 1991 in Malmö, Sweden, Diaverum is part of the [M42](#) group of companies, a global healthcare leader powered by artificial intelligence, technology and genomics to drive healthcare innovation for people and the planet.

### About [M42](#)

M42 is a global healthcare leader powered by artificial intelligence (AI), technology and genomics, driving healthcare innovation for people and the planet.

It combines state-of-the-art specialist facilities with integrated healthcare solutions — including genomics and biobanking — and leverages advanced technologies to deliver precise, preventive and predictive care, transforming traditional healthcare models and positively impacting lives worldwide. Established in 2023 through the combination of G42 Healthcare and Mubadala Health, M42 operates more than 480 facilities across 26 countries and employs over 20,000 people.

Its leading healthcare providers include Cleveland Clinic Abu Dhabi, Danat Al Emarat, [Diaverum](#), Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital and Moorfields Eye Hospital Abu Dhabi.

M42 also operates the Emirati Genome Programme, the Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), the global health technology company managing the Malaffi system.

---

**About Diaverum Portugal**

Diaverum Portugal is one of the leading renal care networks in Portugal, providing specialised treatment and continuous care to approximately 3,500 chronic kidney disease patients across the country. With a network of 28 clinics from north to south, the company stands out for its commitment to clinical quality, therapeutic innovation and human-centred care, contributing daily to improving patients' quality of life and ensuring safe and differentiated access to renal healthcare.

**Media Contacts****EDC Comunicação | Margarida Caparica****Margarida.caparica@edc.pt****+351 91 994 80 20**